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In this study, a hydrophobic material, ethylcellulose, which was used as its aqueous sus-
pension Surelease®, was combined with a swelling agent as the swelling layer to prepare
delayed-release pellets for Danshensu, which is a hydrophilic drug with low MW. A rup-
turable, delayed-release pellet consists of a drug core, a swelling layer containing a
swelling agent (cross-linked sodium carboxymethyl cellulose) with a hydrophobic agent
(Surelease®), and a controlled layer composed by an insoluble, water-permeable polymeric
coating (aqueous ethylcellulose dispersions) was developed in a fluidised bed. Results
showed that blending Surelease® into the swelling layer could effectively extend the
release of Danshensu from the pellets, which may be attributed to the slowed swelling rate
by reduction of water penetration and improvement of mechanical integrity of the swelling
layer. Drug in the delayed pellets showed sustained release in beagle dogs after oral
administration with comparable in-vivo exposure to the uncoated drug pellets. In
conclusion, blends of hydrophobic and swelling agents in the swelling layer in double-
membrane pellets could achieve a delayed drug-release profile in vitro, as well as
delayed and sustained absorption in vivo for highly soluble, low-MW drug. The present; HPLC, high-performance liquid chromatography; DAD, diode array detector; HPMC,
-substituted hydroxypropyl cellulose; CMC-Na, sodium carboxymethyl cellulose; CC-Na,
se; SEM, scanning electron microscope; MRT, mean residence time; AUC, area under
edical Sciences, University of Macau, 3/F, Rm 204A, Block 3, Av. Padre Tomas Pereira, S.J.
4687; fax: þ86 853 28841358.
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MW drugs to meet the formulation requirements for chronopharmacological diseases.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Chronopharmacology is the study of how the effects of drugs
vary with biological timing and endogenous periodicities,
which is relevant to many diseases, such as ischaemic heart
disease and hypertension, which are frequently occurred
before dawn [1]. The circadian rhythms showed that drug
pharmacokinetics and the effects of therapies changed with
the time of drug administration. Therefore, maintaining an
adequate blood concentration during the episodes of a disease
not only improves efficacy but also reduces the side effects of
the drug [2,3].
Delayed-release drug delivery system (DDS) is a chro-
nopharmacology- and hominal physiology-basedDDS,mainly
applied for the treatment of diseases exhibiting circadian
rhythms, for instance, ischaemic heart disease, asthma and
intestinal diseases [4]. Patients may take drug before going to
sleep at around 10 pm, and active components in themedicine
will be released after several hours delay (e.g., 2e4 h) and take
effect at night during the episodes of the disease. As a multi-
particulate DDS, delayed-release pellets are receiving
increasing interest. This administration mode offers many
advantages when compared with normal single-unit delivery
systems, including good reproducibility, generally short
gastric residence time and low risk of dose dumping [5].
There are several approaches to prepare delayed-release pel-
lets, such as pH dependent enteric coating and double-
membrane coating. Most of the double-membrane based
pellets systems contain a drug reservoir surrounded by a
swelling and a controlled layer, which will erode, dissolve, or
rupture [6]. However, the model drugs used in double-
membrane based pellets are mostly western drugs, and few
studies have been performed to produce the delayed release of
low-MW (e.g., ~200) and water-soluble drugs in Chinese
Medicine.
Danshensu (MW 198) is a hydrophilic and quality control
marker of Fufang Danshen Dripping Pill, which has been
officially listed in the Chinese pharmacopoeia [7] and has been
approved by FDA for phase III clinical trial. The main phar-
macological activities of Danshensu include dilating coronary
arteries [8], inhibiting platelet aggregation [9], improving
microcirculation [10] and protecting the myocardium from
reperfusion injury of the ischaemic heart [11]. After oral
administration of Danshensu to rats, Danshensu was quickly
absorbed and rapidly eliminated from the systemic circula-
tion, with a Tmax of 38 min and a t1/2 of 45 min [12]. Moreover,
its oral bioavailability in rat is only about 11% regardless being
delivered as pure compound or herbal extraction [13,14]. As
two widely selling products of Danshen in China, Fufang
Danshen Tablet and Fufang Danshen Dripping Pill are
immediately released dosage forms (q.i.d) and could not meetthe needs of chronotherapeutic treatment for ischaemic heart
disease.
As a low-toxic, non-allergic and non-irritant polymer,
ethylcellulose is a widely used polymer for film coating in
modified-release pellets [15]. In recent years, the use of
organic solutions has been replaced by the aqueous dispersion
Surelease® with the aim of avoiding the toxicity of organic
solvents to the environment, reducing viscosity and loading
higher polymer contents [16e18]. Surelease® is a well-
developed plasticised aqueous dispersion designed specif-
ically for modified-release and taste-masking applications. It
is an aqueous dispersion mainly containing plasticisers and
ethylcellulose. Due to its hydrophobic property, ethylcellulose
was always used as a barrier for water penetration in film and
matrix formation [19].
To take the advantage of the pellets as well as to meet the
requirement of the chronopharmacology for cardiovascular
disease, this study aimed to take Danshensu as a model drug
and develop its delayed-release pellets using double-
membrane system. A rupturable, pulsatile-release pellet
consists of (i) a drug core (Danshensu was used as model
drug); (ii) a swelling layer comprising a swelling agent (CCeNa)
and a hydrophobic agent (Surelease®, aqueous ethylcellulose
dispersions); and (iii) a controlled layer consisting of an
insoluble, water-permeable polymeric coating (Surelease®).
The performance of the pellets was characterised in terms of
morphology, drug release profile and in vivo pharmacoki-
netics in beagle dogs.2. Materials and methods
2.1. Materials
Sodium Danshensu was obtained from Xi'an Hongson
Biotechnology Co. Ltd., China. Sodium Danshensu and caffeic
acid standard substance were obtained from the National
Institute for the Control of Pharmaceutical and Biological
Products, Beijing, China. Suglet® CP-507 (500e700 mm, NP
Pharm, France) was used as the core material for the con-
struction of the spherical, blank and drug-loaded pellets.
Surelease® E-7-19050 (for experimental use only) was obtained
from Colorcon, Shanghai, China. Other excipients of the
delayed-release pellets were hydroxypropyl methylcellulose
(HPMC, Colorcon, Shanghai, China), calcium carboxymethyl
cellulose (CMC-Ca, NICHIRIN, Japan), cross-linked sodium
carboxymethyl cellulose (CCeNa, Ac-Di-Sol SD-711, FMC,
USA), L-hydroxypropyl cellulose (L-HPC, Shin Etsu, Japan),
calcium carboxymethyl cellulose and croscarmellose sodium
(CMC-Ca). All chemical reagents used were at analytical or
HPLC grade.
Table 1 e Summary of fluid bed's parameters during coating for each layer.
Operating condition Set values
Layering of drug Sealed coating
with HPMC
Surelease with CCeNa
as swelling layer
Controlled layer
of Surelease
Before coating
Preheating to (C) 41 41 42 41
Coating
Airflow (Bar)
0.4 0.3 0.3 0.4
Inlet temperature (C) 45 45 50 45
Spray rate (g/min) 0.8 1.0 1.5 1.0
Spray pressure (Bar) 0.85 0.95 1.25 0.9
Product temperature (C) 38e40 37e39 35e37 38e39
After coating
Curing in oven e e 60 C for 2 h 60 C for 2 h
Mesh size (mesh) 30 30 20 20
Table 2 e Samples of pellets with different swelling
agents.
Swelling agent Swelling layer
weight gain
Controlled
layer weight gain
HPMC 20% 20%
CMC-Na 20% 20%
L-HPC 20% 20%
CCeNa 10%, 20%, 30% 20%
CCeNa e Surelease 40% (1:1), 80% (1:3),
120% (1:5)
20%
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2.2.1. Drug core
SodiumDanshensu (0.4 g) was dissolved in 10 g HPMC solution
2% (w/w). Sugar cores (50 g) (Suglet®) were placed into the
fluidised bed (Mini-Glatt 4, Glatt GmbH, Germany) and pre-
heated to 41 C. The coating conditions are summarised in
Table 1. During processing, the spraying rate and inlet air
temperature were fine tuned to maintain the product tem-
perature at 38 ~ 40 C. After coating, the sticking pellets were
removed using mesh in each stage (Table 1). Drug loading rate
was calculated by comparing the drug amount extracted from
the pellets with the initial drug added.
2.2.2. Seal-coating of Danshensu-loaded cores with HPMC
The Danshensu-loaded cores were seal-coated with HPMC 3%
(w/w) before film-coating to prevent the potential interaction
between the drug and the polymers in the swelling layer.
HPMC (1.5 g) was dissolved completely in 48.5 g of water, and
the solution was sprayed onto 50 g of sodium Danshensu-
loaded pellets in a fluidised bed. Then, 30-mesh was used to
remove the sticking pellets.
2.2.3. Optimisation of the swelling layer
Firstly, four swellingmaterials (i.e., HPMC, CMC-Ca, L-HPC and
CCeNa) were screened. The four polymers were individually
mixed with 3% HPMC solution at a ratio of 1:20 (w/w) for the
coating, where HPMC was the binding agent when combined
with the other polymers. Then in-vitro release profiles were
evaluated in terms of three levels of weight gain of CCeNa in
the swelling layer of the pellets. Furthermore, the influence
of blending Surelease with CCeNa was studied. Surelease
(25%, w/w) was added into 500 g water and mixed for
approximately 15 min, and then CCeNa was added into the
Surelease solution andmixedwell. Keeping the weight gain of
CCeNa constant at 20%, suspensions containing CCeNa and
Surelease at ratios of 1:1, 1:3 and 1:5 (w/w) were prepared by
adjusting the amount of Surelease (Table 2). The suspension
was used to coat 50 g of the drug-loaded and sealed pellets.
After coating, the pellets were heat-cured in the oven at 60 C
for 2 h to form complete film. Coating efficiency was calcu-
lated by comparing the solid amount of the coating materials
and the total weight of the coated pellets.2.2.4. Controlled layer coated with surelease
Sureleasewas also used as thematerial in the controlled layer.
Surelease (25%, w/w) was diluted to 15% (w/w) by adding
distilled water while stirring for approximately 15 min. Then,
50 g of pellets were coated with diluted Surelease as the
controlled layer, where its thickness was equivalent to three
different theoretical weight gains of 20%, 25% and 30%. Heat-
curing was performed by using the samemethod as described
in swelling layer preparation, and the actual content of so-
dium Danshensu in the pellets was determined by HPLC.
Coating efficiency was calculated by comparing the solid
amount of the coating materials and the total weight of the
coated pellets.
2.3. In-vitro release test
The in-vitro release profile of Danshensu from the pellets was
determined according to the paddle method described in
Chinese Pharmacopoeia 2010 [7]. The volume of the medium
was 375 ml of 0.1 N HCl for the first 2 h, and then 125 ml of
0.2 N sodium phosphate solution was added to adjust the pH
from 1.2 to 6.8 for the remaining 10 h. The temperature was
37 ± 0.5 C with mechanical stirring at 100 rpm. Pellets con-
taining 10 mg of Dashensu were filled in a gelatin capsule for
the release study. Samples (3.0 ml) were withdrawn from each
vessel at predetermined intervals and replaced with the same
volume of water to maintain the total volume. The samples
were analyzed by HPLC to determine the drug content. Drug
release data from 10% to 80% in the release profile were
selected for fitting using Zero-order, first-order and Higuchi
equations.
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To observe the process of drug release in the release media, a
few pellets with the optimised formula were taken out at 0, 2,
3, 5 and 7 h, respectively from the release test. The pellets
were dried carefully with a tissue and observed by an optical
microscope.
2.5. Scanning electron microscopy (SEM)
Two types of delayed-release pellets containing different
swelling layers (CCeNa alone or with Surelease at a weight
ratio of 1:5) were studied. The pellets were mechanically
cleaved transversely and sputtered with gold. The surface of
the pellets and swelling layers were examined by scanning
electron microscopy (SEM, S-3700, HITACHI) at 10 kV.
2.6. Water vapour permeability of cast films
Three different levels of polymer dispersions containing
CCeNa and Surelease at ratios of 1:1, 1:3 and 1:5 (w/w) were
cast onto a Teflon plate. The films were dried in an oven at
40 C and heat-cured at 60 C for 2 h. The water vapour per-
meabilities of the three different films were determined ac-
cording to the ASTM guideline E 96-00 using the desiccant
method [20]. The thickness of the film was measured by a
micrometre 8 times at different places and the results were
averaged. The film specimen covered the open mouth of a
weighing bottle (~3 cm inner diameter and 3 cm depth) con-
taining 15 g desiccant, which was accurately weighed and
placed into a chambermaintained at 75% RHusing a saturated
sodium chloride solution stored at 25 C. The bottles were
weighed after 48 h to determine the weight gain, and the
waterevapour permeability (P) was calculated using the
following two equations:
WVT ¼ G
tA
(1)
P ¼WVT
S
 ðR1  R2Þ  d (2)
where G is the weight change, t is the time during which G
gained, A is the test area (weighing bottle mouth area), S is the
saturation vapour pressure at the test temperature, R1 is the
relative humidity in the test chamber, R2 is the relative hu-
midity inside the bottle (0% for the desiccant method) and d is
the average thickness of the film [21].
2.7. In-vivo study
2.7.1. Oral administration to beagle dogs
The animal experiment was approved by the internal ethics
committee in University ofMacau (Macau SAR, China). Animal
experiments are conducted in full compliance with national
regulatory principles. The in-vivo performance of the delayed
release pellets with optimized formulation (see Section 2.2.4)
or drug-loaded uncoated pellets (see 2.2.1) were evaluated in
beagle dogs. Three male beagle dogs (weighing 10e14 kg,
provided by Guang Dong Medical and Experimental Animal
Centre) were used. The dogs were fasted for 12 h with freeaccess to water before the drug administration. Danshensu
delayed-release pellets were filled in gelatin capsules and
orally administered to beagle dogs with water at 9 mg/kg of
Danshensu in a single dose. A blood sample of 2 ml was
withdrawn from the forelimb vein of each of the dogs at pre-
determined times and centrifuged at 14,000 rpm for 5 min to
separate the plasma. A sample of 0.5 ml of plasma was
collected, and 0.1 ml 10% HCl containing 5% ascorbic acid was
added to improve the stability of Danshensu in the plasma.
The plasma samples were kept frozen at 20 C until they
were analyzed by HPLC. After a 7-day wash out period
following the last administration, the drug-loaded uncoated
pellets were administered according to the same method as
described above.
2.7.2. HPLC Determination of Danshensu
For the in-vivo pharmacokinetic study, the plasma concen-
tration of Danshensu in the beagle dog was determined by
HPLC according to themethod described in our previous study
[22]. A reverse-phase C18 column (250  4.6 mm, 5 mm, Agilent
Technologies, Inc., Palo Alto, CA, USA) was used with UV
detection at 280 nm. The mobile phase was a 0.5% phosphoric
acid/methanol 82:12 (v/v) mixture and the flow rate was
1.0 ml/min. Good linearity in the range from 0.10 mg/ml to
8.00 mg/ml was obtained with the limit of quantity (LOQ) of
0.04 mg/ml. The accuracy and precision of this method were
acceptable for quantitative analysis.
2.7.3. Pharmacokinetic parameters
The maximum drug concentration (Cmax) and the time to
maximal plasma drug concentration (Tmax) were obtained as
directly measured values. The areas under the plasma con-
centrationetime curve (AUC0-24 h) and mean retention time
(MRT) were calculated by WinNolin software (WinNonlin
version 5.0.1) by assuming a non-compartmental model for
drug absorption and distribution. The lag time of drug
appearance in plasma (Tlag) was defined as the time corre-
sponding to the first appearance of Danshensu in the plasma.
2.8. Statistical analysis
The pharmacokinetic parameters were presented as the
mean ± SD. and Student's t-test was employed for statistical
comparison. A P-value of less than 0.05 was considered as
significant.3. Results and Discussion
3.1. Formulation optimisation
Agglomeration rate and coating efficiency were chosen as the
key indexes to evaluate the pellets coating performance. The
agglomeration rates under all the coating conditions in this
study were below 2%. Drug loading rate was ~90% when using
2% HPMC as the binding agent, and further increased HPMC
concentration could not improve drug loading rate. Therefore,
the following experiment used 2% of HPMC as the binding
agent for drug coating. When CCeNa, L-HPC, CMC-Ca were
mixed with 3% HPMC as the swelling layer, the coating
Fig. 1 e Effect of different CCeNa and Surelease ratios in
the swelling layer on the release of Danshensu
maintaining 20% CCeNa weight gain in the swelling layer
and 20% of Surelease weight gain as the controlled layer
(n ¼ 3).
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that the coating materials were suspension and lack of the
plasticizer. Aftermixing the CCeNawith Surelease andHPMC,
the coating efficiency of the swelling layer were higher than
90%. Moreover, the coating efficiency of the Surelease as the
controlled release layer were all above 90%, all of which
indicting the good coating efficiency for different layers on
fluidized bed.
Preliminary experiments showed that ~70% of the total
drug was sustained released in 12 h from the pellets coated by
a single Surelease layer with 10% weight gain (data not
shown). With an increase in the weight gain of Surelease, the
rate of drug release decreased, and only approximately 35% of
the drug could be released in 12 h at 30% weight gain of
Surelease. These results indicate that with an increase in
Sureleaseweight gain, the rate of drug release from the pellets
decreased, which may be due to that Surelease film controls
the rate of water diffusion into the pellets. If the pellets have
thicker Surelease film, more time will be required for water
diffusion into the pellets. Therefore, to ensure that water
could diffuse into the pellets slowly, at least 20% of Surelease
weight gain was required in the controlled layer.
Using 20% Surelease as the controlled layer, four swelling
materials, including HPMC, CMC-Ca, L-HPC and CCeNa, were
screened. The first three swelling agents are super-disintegrates
that can expand hundreds times after absorbing water, and
HPMC is a polymerhydrogel. Results showed the swelling ability
of thesefourmaterials followedtheorderCCeNa> L-HPC>CMC-
Na > HPMC. The swelling ability of the first two materials was
strong enough to ensure the complete release of Danshensu
after 12 h. However, as CMC-Na and HPMC only have limited
swelling ability, the release of Danshensu using these agents is
more likely to be extended release rather than immediate
release. Thedrug-releaseprofileof thepellets usingHPMCas the
swelling layer displayed sustained release because the swelling
layer of HPMC gelatinises instead of swelling when it absorbs
water.Therefore,CCeNawaschosenastheswellingagent in the
swelling layer to prepare the Danshensu delayed-release pellets
in the following sections.
With 20% Surelease as the controlled layer, the effect of
weight gain of the swelling layer CCeNa on the release of
Danshensu is studied. Only 10% weight gain of CCeNa has
enough swelling ability to crack the controlled layer. However,
evenwhen theweight gain of CCeNawas increased to 30%, no
significant delay could be observed, indicating that the lag
time of the delayed-release pellets could not be achieved
simply by enhancing the weight gain of CCeNa.
The results above showed that delayed-release pellets with
2e6 h lag time could not be realised by only adjusting the
weight gain of the controlled layer and the swelling layer with
the formula used above. Therefore, Surelease, a hydrophobic
material, was blended with the swelling agent in the swelling
layer to decrease the swelling rate of CCeNa. Three types of
delayed-release pellets were prepared to produce different
ratios of Surelease in the swelling layer and keeping weight
gain of the CCeNa constant at 20%. The ratios of CCeNa and
Surelease were 1:1, 1:3 and 1:5 (w/w), with a weight gain of the
controlled layer of 20% in all samples. The release profiles of
the delayed-release pellets are shown in Fig. 1. When the ratio
was 1:1, the lag time of Danshensu was 1.5 h. When the ratiowas increased to 1:3 and 1:5, the lag time extended to 2 h and
3.5 h, respectively. After the lag time, the Danshensu was
released from the pellets quickly, and the drugwas completely
released within 3 h. This result indicated that the lag time of
the delayed-release pellets could be increased effectively by
adding hydrophobic Surelease in the swelling layer. By
increasing the ratio of Surelease in the swelling layer, pellets
with a longer lag time could be prepared. Then, Danshensu
could be released from the pellets rapidly and completely.
Finally, the ratio between CCeNa and Surelease was set at 1:5.
After optimising the swelling layer, the effect of the weight
gain of Surelease in the controlled layer on drug release was
investigated. As shown in Fig. 2, when the weight gain of the
controlled layer was 20%, the lag time of the delayed release
was 3.5 h. With the weight gain increased to 25%, the lag time
was extended to 5 h. When the weight gain was further
increased to 30%, the lag time was extended to 6 h, but the
drug release rate was significantly decreased, and it took 12 h
for the drug to be completely released from the pellets. To
balance the lag time and drug release rate, Surelease at 20%
was used as the controlled layer.
Overall, the optimized formulation of the swelling layer
was set as blending CCeNa and Surelease at a weight ratio of
1:5 with total weight gain of 120%, and the Surelease was used
as the controlled layer with 20% of weight gain with Dan-
shensu loading at 4 mg/g for in-vitro characterization and
12 mg/g for in-vivo pharmacokinetic study.
3.2. The fitting of drug release equation
The in-vitro drug-release profile of the delayed-release pellets
optimised previously was fitted by three different equations,
as shown in Table 3. The drug release of the delayed-release
pellets followed a zero-order equation, indicating that the
release of drug maintained at a constant rate.
3.3. Optical microscopic observation
Optical microscopic pictures of the pellets are shown in Fig. 2.
At 0 h and 2 h, the surface of the delayed-release pellets was
Fig. 2 e Effect of weight gain of Surelease as the controlled layer on drug release when the weight ratio of CCeNa to
Surelease is 1:5 and the total weight gain in the swelling layer is 120% (n ¼ 3).
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 9 9e2 0 7204still intact. Some rifts appeared at 3 h with a small amount of
Danshensu starting to release. At 5 h, the pellets busted and
the core containing Danshensu could make contact with the
medium more completely. The pellets were broken
completely at 7 h, when the core was totally exposed to the
medium and the Danshensu was completely released.3.4. Scanning electron microscopy
SEM results demonstrated that the thickness of the swelling
layer and the controlled layer is around 100 mm and 30 mm,
respectively in the optimized formulation (data not shown).
Fig. 3 showed SEM images of the cross-sections of two types of
pellets with different swelling layers. In the pellets of swelling
layer containing CCeNa and Surelease (Fig. 3A and B) a ho-
mogenous and uniform polymer film was observed. The
compact film could become a barrier between the water and
the drug, preventing the Danshensu from dissolving in the
water before the delayed-release time. Using only CCeNa did
not lead to the formation of compact film (Fig. 3C and D).
However, the filmwas loose and porous. Therefore, there was
a potential risk that the water-soluble drug of a lowmolecular
weight could dissolve into the water, which would penetrate
into the pellets through the pores. This result may explain
why blending hydrophobic Surelease into the swelling layer
can extend the lag time of water-soluble drugs of low molec-
ular weight.Table 3 e The fitted models for drug release from delayed
release pellets.
Model Equation Equation fitted R2
Zero order Mt/M∞ ¼ k t Mt/M∞ ¼ 0.3799 t 0.9867
First order ln(M∞  Mt) ¼ k
t þ M
ln(M∞  Mt) ¼ 0.76
tþ11.946
0.9426
Higuchi M t/M∞ ¼ k t1/2 ln(M∞  Mt) ¼ 1.5904 t1/2 0.98033.5. Water vapour Permeability of cast films
The water vapour permeability of cast films at ratios of 1:1, 1:3
and 1:5 (w/w. CCeNa: Surelease) is (3.64 ± 0.48)  105,
(2.97 ± 0.33)  105, (1.83 ± 0.04)  105 g/Pa$h$m, respectively.
The water vapour permeability of the film composed of
CCeNa and Surelease at a ratio of 1:5 is almost half of those at
a ratio of 1:1, indicating that an increase in the amount of
Surelease results in a decrease in the water vapour perme-
ability of the film and less water could pass through the film.
Due to the hydrophobicity of Surelease, blending Surelease
into the material can prevent water from effectively passing
through the film.
Due to the main ingredient in Surelease, ethyl cellulose,
blending hydrophobic Surelease can effectively improve the
physical structure of the swelling film. It is easier to form a
film with ethyl cellulose than with CCeNa. Therefore, CCeNa
can form a better compact filmwith the help of ethyl cellulose.
The efficiency of the coating and utilisation of coating mate-
rials could also be improved by plasticiser. Water vapour
permeability showed that a higher ratio of Surelease in the
swelling layer led to a longer lag time because more Surelease
in the swelling layer required a longer time for water to
permeate into the swelling layer. A longer lag time must be
achieved to reach enough force for the swelling agent to
rupture the controlled layer and release the drug completely.3.6. In-vivo pharmacokinetic evaluation
The performance of the drug delayed-release system was
evaluated in-vivo. In this investigation, the Danshensu
delayed-release pellets were evaluated by measuring the
plasma concentration profiles of Danshensu after oral
administration of coated and uncoated pellets. The mean
concentration-time curves for the Danshensu delayed-release
pellets and the uncoated pellets in three beagle dogs are
illustrated in Fig. 4, and all the pharmacokinetic parameters
were calculated using WinNolin and are listed in Table 4.
Fig. 3 e SEM graphs of Danshensu delayed-release pellets: (A) cross-section of the pellets using CCeNa and Surelease at the
ratio of 1:5 (w/w) with 120% weight gain as the swelling layer; (B) magnification of the swelling layer composed of CCeNa
and Surelease; (C) cross-section of the pellets only using CCeNa as the swelling layer; (D) magnification of the swelling layer
of CCeNa.
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beagle dogs, Danshensu appeared in plasma immediately
without any lag time, and then the blood concentration of
Danshensu sharply increased with a Tmax of 1.08 ± 0.38 h.
While the delayed-release pellets showed a 1.5 ± 0.41 h lag
time, and the Tmax was significantly extended to 3.33 ± 0.58 h,
T1/2 and MRT also significantly increased from 1.90 ± 1.40 h to
2.51 ± 0.33 h and from 1.50 ± 0.43 h to 6.36 ± 1.04 h, respec-
tively. These results indicated that the double-layer delayed-
release pellets developed could retard drug release in-vivo andFig. 4 e Plasma concentration-time profiles of Danshensu
after oral administration of drug-loaded pellets or drug
loaded delayed-release pellets of Danshensu at 9 mg/kg in
beagle dogs (n ¼ 3). Pellets were coated using CCeNa and
Surelease at the ratio of 1:5 (w/w) with 120% weight gain as
the swelling layer, and Surelease layer at 20% weight gain
as the controlled layer at drug loading of 12 mg/g.maintain the drug in the body for a longer time. In addition,
Cmax significantly decreased from 3.42 ± 0.72 mg/ml to
0.74 ± 0.28 mg/ml and AUC remained unchanged. These results
suggest that after the lag time of drug release, Danshensuwas
released in a sustainedmanner rather than immediately from
the pellets.
Although the pulsatile release in vitro is obvious, the
plasma drug concentration-time plot showed significantly
sustained absorption and elimination profiles. This apparent
disparity may be due to several reasons. One possible reason
may be that only limited gastric fluid are available in beagle
dog's stomach and intestine, while there is plenty of medium
used in the in-vitro release experiments. Therefore, swelling
layer of pellets in the GI tract may not absorb enough water
and break up the controlled layer as quickly as those under in-Table 4 e Pharmacokinetic parameters of Danshensu
pellets after oral administration in beagle dog (n ¼ 3).
Parameters Uncoated
pellets [22]
Delayed release
pellets
Tlag (h) 0.00 ± 0.00 1.50 ± 0.41
*
Tmax (h) 1.08 ± 0.38 3.33 ± 0.58
*
T1/2 0.65 ± 0.26 2.51 ± 0.33
*
MRT (h) 1.50 ± 0.43 6.36 ± 1.04*
Cmax (mg/ml) 3.42 ± 0.72 0.74 ± 0.28
*
AUC (mg*h/ml) 5.22 ± 1.48 3.91 ± 1.16
All the data are presented in the form of Mean ± SD.
* Statistically significant difference compared to uncoated pellets
(P < 0.05).
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and elimination. Another possibility may be that the absorp-
tion of Danshensu occurs mainly in the small intestine [23].
While this delayed-release system has a lag time, it might
cause some pellets to reach the colon before the entire drugs
are completely released. And it is expected that the absorption
of Danshensu in the colon is poor, leading to a reduced ab-
sorption and elimination.
Although the delayed-release pellets showed a much
longer Tlag and higher MRT than the uncoated pellets, their
Tlag was shorter than the value obtained from the in-vitro
drug-release studies. The variation between the in-vitro and
in-vivo results may be caused by two reasons. Firstly, the
developed pellets are both time- and pH-dependent, as the
swelling ability of CCeNa depends on the pH value (data not
shown). The higher pH value, the stronger swelling ability of
CCeNa is [24]. Secondly, there are many physiological differ-
ences between humans and dogs [25], such as the gastric
emptying time (0.19 h) and intestinal transit time (3.40 h),
which are both much shorter in dogs than those in humans.
The in-vitro release conditions (e.g., time and pH) used in the
present study simulated human GI conditions, which are not
consistent with the in-vivo GI conditions of a beagle dog.
Therefore, the delayed-release pellets would contact the high
pH value environment earlier in beagle dogs than those in the
release test, where the CCeNa could swell faster, which may
contribute to the shorter lag time in the in-vivo pharmacoki-
netic study. Furthermore, the gastric mechanical destructive
abilities of the beagle dog (3.2 N) are stronger than those of
humans (1.5 N) [26], so some pellets may be more easily
damaged in beagle dogs, whichmay be another reason for the
shorter lag time in the in-vivo study. All of these factors led to
the poor correlation between the in-vitro and in-vivo perfor-
mances of the coated pellets. To better simulate human con-
ditions, GI physiology regulated dogs, whose gastric pH,
gastric emptying time and small intestine transit time are
almost identical to those of the humanmay be considered for
future work. Murata et al. [25] regulated beagle dogs' GI
physiology by a combined treatment of intramuscular injec-
tion of pentagastrin (10 mg/kg, bid, with a 45 min interval)
with intravenous injection of atropine sulphate (0.02 mg/kg).
They have demonstrated good correlation between in-vitro
and in-vivo studies.4. Conclusions
To achieve a delayed drug-release profile for highly soluble
low-MW drugs, blends of hydrophobic and swelling agents in
the swelling layer are required. The lag timewas controlled by
the coating level of the swelling and controlled layer, as well
as the ratio between the hydrophobic agent and the swelling
agent in the swelling layer. Blending Surelease in the swelling
layer retards water penetration and enhances the mechanical
structure of the film by slowing the swelling rate of CCeNa.
The drug-release mechanism controlled by the rupturing of
the outer layer was confirmed by microscopic observations of
pellet behaviour during release, where the drug release fol-
lowed a zero-order equation. In-vivo results confirmed thedelayed and sustained absorption of Danshensu in beagle
dogs for the coated pellets. The present study highlighted the
potential use of the delayed-release system for other hydro-
philic low-MW drugs to meet the formulation requirements
for chronopharmacological diseases.Acknowledgements
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